Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480658 | 0.92 | KCNH2 (0.55) | KCNH2MAPTALDH1A1DRD2DRD4 | |
| SCHEMBL378659 | 0.92 | KCNH2 (0.55) | KCNH2MAPTALDH1A1DRD2DRD4 | |
| SCHEMBL519168 | 0.83 | DRD2 (0.58) | KCNH2MAPTALDH1A1DRD2DRD4 | |
| SCHEMBL14150420 | 0.82 | LTA4H (0.53) | LTA4H | |
| SCHEMBL31493409 | 0.82 | ALDH1A1 (0.56) | KCNH2POLBMAPTALDH1A1DRD2 | |
| SCHEMBL4937120 | 0.81 | HRH3 (0.57) | KCNH2MAPTALDH1A1DRD2DRD4 | |
| SCHEMBL6228523 | 0.80 | MAPT (0.65) | KCNH2POLBMAPTALDH1A1DRD2 | |
| SCHEMBL17971426 | 0.80 | HRH3 (0.60) | KCNH2MAPTDRD2DRD4DRD3 | |
| SCHEMBL28180977 | 0.80 | HRH3 (0.60) | KCNH2MAPTDRD2DRD4DRD3 | |
| SCHEMBL28180976 | 0.80 | HRH3 (0.60) | KCNH2MAPTDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| EP-3731840-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | Orfan Biotech Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | PNPO, XDH, GLS | KCNH2 1883/4885POLB 1927/4885MAPT 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.